BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 38528605)

  • 1. Role of ten-eleven translocation proteins and 5-hydroxymethylcytosine in hepatocellular carcinoma.
    Wang P; Yan Y; Yu W; Zhang H
    Cell Prolif; 2019 Jul; 52(4):e12626. PubMed ID: 31033072
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epigenetic Modification of Cytosines in Hematopoietic Differentiation and Malignant Transformation.
    An J; Ko M
    Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36675240
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Coordinated activation of DNMT3a and TET2 in cancer stem cell-like cells initiates and sustains drug resistance in hepatocellular carcinoma.
    Cheng T; Zhou C; Bian S; Sobeck K; Liu Y
    Cancer Cell Int; 2024 Mar; 24(1):110. PubMed ID: 38528605
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of active demethylation and 5hmC formation by 5-azacytidine is TET2 dependent and suggests new treatment strategies against hepatocellular carcinoma.
    Sajadian SO; Ehnert S; Vakilian H; Koutsouraki E; Damm G; Seehofer D; Thasler W; Dooley S; Baharvand H; Sipos B; Nussler AK
    Clin Epigenetics; 2015; 7(1):98. PubMed ID: 26366235
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation of DNA methylation of DNMT3A and TET2 with oral squamous cell carcinoma.
    Li X; Li Z; Gao Q; Peng Y; Yu Y; Hu T; Wang W
    Discov Oncol; 2024 Jan; 15(1):15. PubMed ID: 38246976
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epigenetic silencing of TET2 and TET3 induces an EMT-like process in melanoma.
    Gong F; Guo Y; Niu Y; Jin J; Zhang X; Shi X; Zhang L; Li R; Chen L; Ma RZ
    Oncotarget; 2017 Jan; 8(1):315-328. PubMed ID: 27852070
    [TBL] [Abstract][Full Text] [Related]  

  • 7. miR-4270 suppresses hepatocellular carcinoma progression by inhibiting DNMT3A-mediated methylation of HGFAC promoter.
    Zou Q; Cao S
    PeerJ; 2023; 11():e16566. PubMed ID: 38077422
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human menstrual blood-derived stem cells reverse sorafenib resistance in hepatocellular carcinoma cells through the hyperactivation of mitophagy.
    Zhou S; Liu Y; Zhang Q; Xu H; Fang Y; Chen X; Fu J; Yuan Y; Li Y; Yuan L; Xiang C
    Stem Cell Res Ther; 2023 Apr; 14(1):58. PubMed ID: 37005657
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sorafenib Resistance in Hepatocellular Carcinoma: The Relevance of Genetic Heterogeneity.
    Cabral LKD; Tiribelli C; Sukowati CHC
    Cancers (Basel); 2020 Jun; 12(6):. PubMed ID: 32549224
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted sequencing reveals the mutational landscape responsible for sorafenib therapy in advanced hepatocellular carcinoma.
    Tang J; Sui CJ; Wang DF; Lu XY; Luo GJ; Zhao Q; Lian QY; Jeong S; Lin XM; Zhu YJ; Zheng B; Wu R; Wang Q; Liu XL; Liu JF; Xia Q; Wu G; Gu J; Wang HY; Chen L
    Theranostics; 2020; 10(12):5384-5397. PubMed ID: 32373219
    [No Abstract]   [Full Text] [Related]  

  • 11. Role of m
    He Y; Yu X; Li J; Zhang Q; Zheng Q; Guo W
    Am J Transl Res; 2020; 12(3):912-922. PubMed ID: 32269723
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protein lysine 43 methylation by EZH1 promotes AML1-ETO transcriptional repression in leukemia.
    Dou L; Yan F; Pang J; Zheng D; Li D; Gao L; Wang L; Xu Y; Shi J; Wang Q; Zhou L; Shen N; Singh P; Wang L; Li Y; Gao Y; Liu T; Chen C; Al-Kali A; Litzow MR; Chi YI; Bode AM; Liu C; Huang H; Liu D; Marcucci G; Liu S; Yu L
    Nat Commun; 2019 Nov; 10(1):5051. PubMed ID: 31699991
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epigenetic evolution and lineage histories of chronic lymphocytic leukaemia.
    Gaiti F; Chaligne R; Gu H; Brand RM; Kothen-Hill S; Schulman RC; Grigorev K; Risso D; Kim KT; Pastore A; Huang KY; Alonso A; Sheridan C; Omans ND; Biederstedt E; Clement K; Wang L; Felsenfeld JA; Bhavsar EB; Aryee MJ; Allan JN; Furman R; Gnirke A; Wu CJ; Meissner A; Landau DA
    Nature; 2019 May; 569(7757):576-580. PubMed ID: 31092926
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting DNA Methylation and EZH2 Activity to Overcome Melanoma Resistance to Immunotherapy.
    Emran AA; Chatterjee A; Rodger EJ; Tiffen JC; Gallagher SJ; Eccles MR; Hersey P
    Trends Immunol; 2019 Apr; 40(4):328-344. PubMed ID: 30853334
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytosine-Based TET Enzyme Inhibitors.
    Chua GNL; Wassarman KL; Sun H; Alp JA; Jarczyk EI; Kuzio NJ; Bennett MJ; Malachowsky BG; Kruse M; Kennedy AJ
    ACS Med Chem Lett; 2019 Feb; 10(2):180-185. PubMed ID: 30783500
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.